Objective: In ongoing protocols worldwide the frequency of relapses in malignant CNS GCT under platinbased treatment regimen can be estimated as about 15% for germinoma and 30% for secreting CNS GCTs. Recurrent malignant intracranial CNS Germ Cell tumors especially if of non-germinomatous histology carry a poor prognosis. According to experience of published series nearly all patients with recurrence after a nongerminomatous CNS GCT died. Therefore the attempt of recent protocols is to evaluate treatment strategies for recurrent malignant CNS GCT to achieve better overall outcome results. Within the SFOP (Sociėtė Francais d'Oncology Pediatrique) protocols of the 90ies, 73 patients with germinoma were treated. In SIOP (Societe International D'Oncology Pediatrique) CNS GCT 96, 150 protocol patients with germinoma were registered. For secreting tumors (YST, CHC, EC ) 38 patients were protocol patients in the SFOP studies and 109 in SIOP CNS GCT 96. Patients and initial treatment: In the SFOP studies all patients with germinoma received a combined treatment with 2 courses Carbo/VP16/Ifosfamid followed by radiotherapy (RT), which was focal (40 Gy) in localized disease or craniospinal (CSI) in metastatic disease. In SIOP CNS GCT 96 pts were either treated with chemo (CT) and focal RT equally to the SFOP studies or receive craniospinal RT (24/16 Gy). For secreting tumors in the SFOP studies patients received 4-6 courses CT followed by focal RT (54 Gy) or CSI (30/24 Gy ) in metastatic disease. Some of the patients (TGM95) had CT alone, to evaluate the remission rate with CT only. In SIOP CNS GCT96 all pts with localized tumors were treated with 4 courses Cisplatin/VP16/Ifos-famide followed by focal RT (40Gy) in localized tumors and by CSI (30/24Gy) in disseminated disease. Profile of patients with recurrence: Germinoma: Within the SFOP studies for germinoma, 9 relapses occured, 8 in pts with localized disease and one in a pt with disseminated tumor. 6 pts had ventricular relapses, one a local, one a spinal relapse and one a recurrence outside the ventricles. All were treated with conventional therapy (VP16/Carbo, VIP) to achieve again a biological remission, which was possible in 7 pts, one had a inoperable tumor residuum and one show only partial response. In SIOP CNS GCT96, 8 relapses occurred, 4 after combined treatment and 4 after CSI. All were treated with chemotherapy again (PEI or VP16/Carbo), all responded very well, 7/8 achieved complete biological remission. One had a tumor residual which came out to be mature teratoma. Secreting tumors: In the SFOP studies 10 relapses were reported. 7 had spinal relapses, combined with intracranial lesions in 3. Three were local (2) or ventricular (1) . All received additional chemotherapy VP16/DDP or VIP. Biological remission was obtained in 7 pts. In SIOP CNS GCT 96, 25 relapses occurred. Relapses were mainly local (14) , spinal (4) and combined (local and spinal: 6), one had an abdominal relapse. Also in this cohort additional platinbased chemotherapy led to a complete or nearly complete biological response. Patients with High dose treatment: Germinoma: 8/9 of the SFOP series received high-dose treatment (HDC) with VP16/Thiotepa, two cycles (VP16 3x500 mg/m2, Thiotepa 3x300 mg/m2). 4 achieved a long term remission, 4 relapsed again, of whom 1 died and 2 were salvaged by HDMTX and RT and one is under third line treatment. Within the SIOP Protocol in germinoma 3/8 relapsing patients had high dose treatment with Carbo/VP16/Thiotepa; VP16/Thiotepa. 2/3 are alive the other 5/8 had irradiation after conventional treatment. 3 survived , two died of disease. Secreting tumors: 7/10 relapsed pts in SFOP received HDC after recurrence and second line treatment. 3 are alive after VP16/Thiotepa. In SIOP CNS GCT96 9/25 received HDC. 2 are in remission, 2 have just finished their treatment. Side effects: Reported side effects were moderate with panzytopenia and mucositis. Conclusion: HDC in recurrent CNS GCT is a possible treatment option when biological remission is achieved prior to HDC. In the new SIOP protocol HDC will be used within the first line in patients with insufficient response to primary chemo. 
C. Uderzo on Behalf of EBMT PWP and I-BFM-SG (Monza, I)
Summary : Despite very intensive first line protocols the results concerning the treatment of Childhhod VHR ALL have been relatively dismal . Different combinations of risk factors at the diagnosis were used to design first-line protocols and this variable strategy reflects statistical variation on event free survival obtained by single or multicenter studies in this particular cathegory of patients. Since 1995 the EBMT and I-BFM-SG set up a prospective randomized trial with the aim to compare the role of AlloBMT vs.CHEMO in the treatment of VHR childhood ALL. The homogeneous criteria adopted in defining VHR patients at diagnosis were as follows: cytogenetic abnormalities as t(9;22) or t(4;11), Prednisone poor response and T-ALL or WBC more than 100.000/mm3, induction failure. Patients having a suitable HLA A,B,DR sibling donor underwent AlloBmt as soon as they obtained the 1st CR. Relevant features of this study covered an area of particular interest by a multicenter study ( 392 VHR ALL patients recruited in 5 years with a median follow up of 50 months) based also on common BFM "first line protocol" and on prospective HLA typing (allowing a "biological randomization") which was performed at the time of the attainment of the first complete remission (CR). The main goal of this cooperative study was to recruit a sufficient number of patients in order to perform an intention to treat analysis and to overcome the selection bias regarding the allocations to transplant and chemotherapy . The final analysis is underway and will be presented within the 2002. The preliminary result yelds an extremely high participation to the study ( 92% of the recruited patients, i.e.360/392, are evaluable for the analysis). Looking at the assigned arm by genetic chance 267/ 360 performed chemotherapy (20/267 despite an available sibling donor), 50/360 underwent an AlloBmt from sibling donor, 26/360 underwent a MUD BMT and 17/360 an alternative donor BMT . The 5 years overall survival ( 53%) and DFS (44%) promt the participating Centers to continue to improve in the future the strategies for the VHR ALL children. The significative advantage for donor versus "no donor" cohort of patients ( 5 years DFS = 58% vs 40% respectively) outlines the importance of the intention to treat analysis in this intergroup large study. As a matter of fact some deviations from the study in that some patients performed also a match/mismatch unrelated donor BMTs or alternative donor BMT have been adjusted and correctly evaluated only by this particular approach.
From the current study other interesting features emerge if one consider the improvement, compared with the hystorical data, obtained by chemotherapy arm in the subgroup of patients with prednisone poor responder and T-immunophenotype and/or hyperleukocytosis at the diagnosis ( 4 years DFS = 54% ). Considering this and other results of this study one might consider chemotherapy and/or transplantation options in a more dinamic way as the literatura claimed in the past . Other subgroups of patients such those with genetic translocations associated with prednisone poor response or those who failed to obtaine first complete remission seem to be still at bad prognosis . In this category of patients more effort for a better therapy should be paid in the future both with chemotherapy and with any kind of hemopoietic stem cell transplantation . In conclusion despite the current cooperative study proved a consistent improvement in the treatment of Childhood VHR ALL, future challenges regard the reduction of the relapse rate which still constitues the most frequent cause of treatment failure especially in CHEMOpatients; however the reduction of transplant-related mortality by means of better supportive therapy would extend confidence mostly in transplantation from unrelated or alternative donors.
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Graft versus host disease
G. Dini (Genoa, I)
Graft-versus-Host Disease (GvHD) remains the most significant obstacle to successful allogeneic hematopoietic stem cell transplantation (HSCT). Acute (a) GvHD is a clinicopathological syndrome involving the skin, liver, and gut, that develops within 100 days of HSCT. The term chronic (c) GvHD describes a more pleiotropic syndrome that develops after day 100. Pathogenetic criteria for GvHD development were defined by Billingham in 1966 (1) . More recently, a multistep mode of antigen expression, cytokine production, T-cell activation, and tissue injury has been described (2,3). A-grade II-IV GvHD occurs in 35% of children receiving cyclosporin (CsA) alone as GvHD prophylaxis after HSCT from a matched sibling donor (MSD) (4). Recipient age below 20 years significantly correlates with lower risk of a-GvHD (5). Gender mismatching has no significant incidence in this setting (4). C-GvHD occurs in 25% of children given an MSD, and in one third of these cases this occurs in an extensive form. In multivariate analysis, the variables predicting development of c-GvHD are: grade II-IV a-GvHD, female donor for male recipient, diagnosis of malignant disease, and use of radiotherapy during the preparative regimen (6) . Prevention A combined regimen of Methotrexate (MTX), given on days 1, 3 ,6, and 11 ("short" MTX), and a 180-day course of CsA was compared to either drug used alone, and was shown to reduce GvHD and improve survival in adult patients given an MSD for severe aplastic anemia or for leukemia (7, 8) . Adding prednisone was of no benefit (9) . Recently, a 10-year follow-up of a randomized study showed that low-dose (1 mg/Kg) CsA given as a single drug, and low CsA serum levels in the first 10 days after HSCT confers significant protection against leukemia relapse in patients below 30 years of age with leukemia (10). Transplant-related mortality (TRM) was similar in both groups of patients, and 10-year disease-free survival (DFS) was significantly higher in patients given "low" dose CsA (11) . This has been confirmed in a randomized trial performed on children, which compared CsA 1 mg/kg vs CsA 3 mg/Kg. A single center trial utilizing "early" CsA from day -7 associated with "short" MTX showed improved results in adults given an unrelated (UD) donor HSCT as compared to historical data (12) .The efficacy of "early" CsA, compared to "standard" CsA in children given UD HSCT for malignancies is under investigation. As far as the duration of CsA prophylaxis is concerned, a prospective, randomized trial comparing 24 month to 6 month administration showed that the risk of developing c-GvHD was not significantly different in the two groups. In addition, there were no significant differences between the two groups as far as TRM, survival, or DFS were concerned (14) . Two multicenter trials showed the superiority of Tacrolimus/MTX compared to CsA/MTX. A-GvHD was significantly lower both after unrelated and sibling HSCT with no increase in toxicity, infections, or leukemia relapse in adult patients (15, 16) . Recently, Tacrolimus was confirmed to be well tolerated and effective in pediatric patients undergoing HSCT (17) . A prospective study by the AIEOP BMT Group comparing "early" CsA with "early" Tacrolimus, both used at "low" doses in children given an MSD HSCT, is ongoing. The addition of anti-human thymocyte globulin (ATG) to standard GvHD prophylaxis showed a benefit to patients given an unrelated donor (UD) HSCT (18), but did not alter the incidence or severity of GvHD in patients given matched sibling HSCT. Recently, it has been shown that large doses of highly purified CD34+ stem cells lead to the elimination of GvHD, without increasing rejection or the relapse rate in patients given a haploidentical HSCT (19) . Treatment Primary therapy of a-GvHD Most centers consider a tapering schedule of 2 mg/kg/day Methylprednisolone (MP) as the standard therapy for established grade II-IV a-GvHD. Early treatment of a-GvHD with MP 10 mg/kg/day does not improve the response rate as compared to 2 mg/kg/day, nor does it influence TRM and survival. A group of patients at high risk of TRM can be identified after 5 days of treatment with MP 2 mg/kg, and they would therefore be eligible for alternative forms of therapy (20) . Adding ATG or monoclonal antibodies to the standard primary therapy does not produce any benefits (21) (22) (23) . Secondary therapy of a-GvHD Patients in whom initial therapy failed (defined as GvHD "not resolved" or "not improved" after 5 days of 2 mg/kg MP or "progressed" after 3 days) have received a variety of salvage regimens. Changing immunosuppressive therapy from CsA to Tacrolimus produced benefits in 12% of cases (24) . Early administration of ATG compared to MP, 5 mg/kg/day in adults at high risk of TRM (20) is under investigation in a prospective study by the Italian group for HSCT. Sirolimus (Rapamycin) is a macrolide from streptomyces hygroscopicus. When it was used as secondary therapy in 21 patients, it led to 5 complete responses (CRs) and 7 partial responses (PRs), with 29% survival. Dose limiting toxicity was marrow hypoplasia (25) . Recently, several monoclonal antibodies have been used as secondary therapy for steroid-refractory a-GvHD. Przepiorka et al. reported that 29% to 53% of patients treated with daclizumab, humanized monoclonal IgG1 directed against the alfa-chain of the IL-2 receptor achieved CR and survived at 120 days, but 40% of these patients subsequently required additional therapy with ATG (26) . Infliximab, a chimeric human/mouse anti TNF-alfa antibody produced CR of diarrhea and significant improvement of skin and liver disease in three of four patients with severe a-GvHD not responding to treatment with steroids (27) . Forty percent to 50% of patients with steroid refractory a-GvHD responded for at least 7 days, and survived at 180 days after treatment with ABX-CLB, an anti-human CD147 murine monoclonal antibody. Moderate to severe myalgia occurred in 28% to 60% of patients and was dose-limiting (28). More recently, 17 patients with steroid refractory a-GvHD were enrolled in a phase 1 study to test visilizumab, a humanized anti-CD3 antibody. A single dose of 3 mg/m2 resulted in 6 CRs and 3 PRs, in a group of 9 patients, among whom 7 patients survived after a median of 1 year. The authors conclude that a phase 2 study is warranted (29) . During the last 5 years, Extracorporeal Photochemotherapy (EPC) has been reported as an alternative option which can cure more than 60% of patients with resistant acute and chronic GvHD (30,31). An ongoing study by the BMT Group of the AIEOP is comparing early extracorporeal photochemotherapy (EPC) to MP, 5 mg/kg/day in childhood aGvHD resistant to primary therapy. Treatment of c-GvHD The CsA-MP combination is the standard therapy for c-GvHD (32). The Baltimore team reported encouraging results with the use of thalidomide in high risk patients (33), but a prospective, randomized trial from the Seattle team did not confirm these data. Neutropenia and neurologic symptoms were the most frequent reasons for early discontinuation of thalidomide treatment (34). Mycophenolate mofetil (MMF) in combination with other immunosuppressive agents may play a role in children with refractory C-GvHD (35). Summary In summary, CsA alone or in association with "short" MTX is considered the standard prophylaxis for GvHD in children given an MSD HSCT. The optimal dosage and duration of CsA immunosuppression is yet to be better defined. Tacrolimus seems to be an attractive alternative to CsA. Several centers have recommended the addition of ATG for children undergoing UD HSCT. A tapering schedule of 2 mg/kg/day MP is considered the standard primary therapy for established aor c-GvHD, but system steroids are not the best strategy. Future directions for GvHD trials include: MMF, Sirolimus, and monoclonal antibodies such as daclizumab and visilizumab. Cooperative studies are warranted to hasten progress. 
Immune therapy 58 CMV-specific immunotherapy
H. Einsele (Tubingen, D)
An increased understanding of the mechanisms by which T cells recognize virus and tumor-specific antigens has stimulated much interest in the use of specific T cells as adoptive immunotherapy for viral and malignant diseases. Unselected populations of lymphocytes from the peripheral blood of the donor usually contain CMV-specific T cells and therefore can be used to control CMV infection. However, the utility of such therapy is limited by potentially fatal complications that arise from alloreactive T cells also present in the donor lymphocyte infusion. A further problem of using unselected populations of donor lymphocytes is the rather low frequency of CMV specific T cells in the donor lymphocyte preparation . The transfer of syngeneic (i.e., involving genetically identical donors and recipients), polyclonal CD8+ T cells from immune mice to immunosuppressed mice provided protection from a viral challenge. In humans polyclonal populations of lymphocytes obtained from the peripheral blood of the donor have been used successfully to treat the Epstein-Barr virus (EBV) lymphoproliferative syndrome that can develop after allogeneic bone marrow transplantation. However, the transfer of these unselected lymphocytes also caused graft-versushost disease (GVHD). Enrichment of the lymphocytes in cytotoxic T cells specific for EBV by in vitro culture before transfer appears to reduce the risk of GVHD. A more definitive strategy to reduce the risk of GVHD from allogeneic lymphocytes is to use T-cell clones with specificity for the antigens of the pathogen being treated. Clones of cytotoxic T lymphocytes specific for CMV can be isolated from normal CMV-seropositive subjects. The predominant specificity of these clones is directed against CMV structural proteins, such as the matrix proteins pp65 and pp150, which are presented for recognition by cytotoxic T lymphocytes before new virions are formed in infected cells. CMV-specific T cells can also be generated by repetitive stimulation with antigen-presenting cells presenting CMVderived peptide antigens. Most often CMV-infected fibroblasts have been used very effectively as antigen-presenting cells for stimulating CMV-specific CD8+ CTLs. But there has been concern about the potential for viral reinfection concurrent with adoptive cellular therapy.
Thus, antigen-presenting cells pulsed with either CMV protein or immunogeneic CMV peptides are increasingly used to try to generate and to expand CMV-specific T cells. Depending on the APC used (monocytes vs dendritic cells) and the mode of antigen presentation (protein vs peptide pulsing) different CMV-specific T cell populations of varying frequency can be generated. As CMV-specific CD4+ and CD8+ T cells are required to mount an efficient and persistent CMV-specific T cell response, combination of these approaches described might be useful to optimize T cell generation for adoptive immunotherapy.
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Donor lymphocyte infusion following reduced intensity allografting
K. Peggs (London, UK)
Incorporation of alemtuzumab in conventional allogeneic conditioning protocols is a well-described and efficacious form of graft-versus-host disease (GVHD) prophylaxis. Extension into the reduced intensity setting appears to be similarly effective with both HLA-matched sibling and matched unrelated donors(1;2). However, the reduced anti-tumour activity of these protocols combined with extensive immunosuppression may require the early use of adjuvant donor lymphocyte infusions (DLI) in order to promote graftversus-malignancy activity. Since the development of mixed chimerism may herald disease relapse or graft failure its development may also prompt the use of DLI. The timing and dosage of DLI that can be administered with relative safety remain poorly defined, particularly in the reduced intensity setting where persistent host antigen presenting cells (APCs) could have a significant impact on the development of GVHD. We have therefore examined the toxicity and efficacy of an escalating dose DLI protocol following reduced intensity allografting with a conditioning regimen consisting of alemtuzumab 20mg/day on days -8 to -4, fludarabine 30mg/m2/day on days -7 to -3 and melphalan 140 mg/m2 on day -2. These data are from an adult cohort (median age 46, range 22-59) but may provide some informative principles for application in the paediatric setting. DLI was contraindicated in the presence of active GVHD. Unmanipulated T-cells were given either for residual disease or mixed chimerism from 6 months post transplantation, or for disease progression at any time point. The initial dose for the first 2 indications was 1x106 CD3+ T-cells/kg, with incremental T-cell doses (up to 1x108/kg) administered at 3 monthly intervals in the absence of GVHD if residual disease or mixed chimerism persisted. The doses for progressive disease depended on the timing post-transplantation. Forty-two patients received a total of 86 doses of DLI. Thirty were HLAmatched sibling transplants, 7 fully HLA-matched and 5 mismatched unrelated donor transplants. Seven had previously developed Grade I-II GVHD following transplantation, which was quiescent at the time of DLI. Indications were mixed chimerism alone in 11 cases, residual disease in 12 (all mixed chimeras) and progressive disease in 18 (12 mixed chimerism, 3 full donor chimerism, 3 not tested). Two of the former group received further doses for subsequent disease progression. Six patients developed Grade I-II and 9 Grade III-IV GVHD following DLI. Of particular note, GVHD was significantly more common and severe in the unrelated donor cohort (9/11 evaluable patients). In all these cases GVHD occurred at the initial T-cell dose, including 6 cases at a dose of 1x106/kg at 6 months post-transplantation (compared to 0/22 in the sibling transplants). All those cases with unrelated donors and a previous history of GVHD following transplantation (n=3) developed Grade III-IV GVHD. 26/33 evaluable patients converted to full donor chimerism, and in the sibling transplants this conversion was often achieved without GVHD. In a minority of cases developing GVHD there was a state of persistent mixed chimerism (3/15 evaluable). One case with full donor chimerism prior to DLI developed GVHD. No disease responses were documented in the absence of conversion to full donor chimerism, but subsequent disease progression was often seen despite persisting full donor chimerism (in the
